Haemonetics (HAE) Operating Income (2009 - 2026)

Haemonetics has reported Operating Income for 18 years, with the latest figure at -$23.0 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Income fell 132.28% year-over-year to -$23.0 million; the trailing twelve-month figure through Mar 2026 stood at $156.7 million (down 29.34% YoY), and the FY2026 full-year result was $156.7 million, down 29.34% from the prior year.
• Operating Income for Q1 2026 stood at -$23.0 million, down from $67.4 million in the prior quarter.
• The five-year high for Operating Income was $71.3 million in Q1 2025, with the low at -$23.0 million in Q1 2026.
• Average Operating Income over 5 years is $41.9 million, with a median of $44.6 million recorded in 2022.
• Year-over-year, Operating Income surged 2113.45% in 2022 and slumped 132.28% in 2026.
• Tracing HAE's Operating Income over 5 years: stood at $43.3 million in 2022, then climbed by 6.24% to $46.0 million in 2023, then rose by 28.39% to $59.0 million in 2024, then climbed by 14.17% to $67.4 million in 2025, then tumbled by 134.16% to -$23.0 million in 2026.
• The last three Operating Income figures came in at -$23.0 million (Q1 2026), $67.4 million (Q4 2025), and $58.5 million (Q3 2025), per Business Quant data.

Peer Comparison